FAP-DMD: Elucidating the role of FAP cells in the process of muscle degeneration in patients with Duchenne muscular dystrophy

FAP-DMD:阐明FAP细胞在杜氏肌营养不良症患者肌肉退化过程中的作用

基本信息

  • 批准号:
    MR/W019086/1
  • 负责人:
  • 金额:
    $ 107.87万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    未结题

项目摘要

Duchenne muscular dystrophy (DMD) is a devastating disease produced by mutations in the dystrophin gene. Disease's onset with onset of weakness occurs before the age of 5 years and progresses leading to loose of ambulation during adolescence. Patients die during the third decade of life because of cardiac or respiratory complications. The only treatment approved so far is corticoids that slow down progression but without having a real impact in natural history. Despite huge efforts invested in developing new treatments, most of them have failed. At the moment, gene therapies based on the release of a healthy copy of the dystrophin gene to the muscle fibers are showing promising results, but it seems clear that they are not going to be able to stop disease's progression and that the process of muscle degeneration will remain active. The process of muscle degeneration in DMD has been studied for many years in animal models of the disease. Lack of dystrophin makes the fibers more susceptible to damage during normal muscle contraction. Damaged fibers are initially repaired by cells named satellite cells. However, repetitive damage triggers a series of consequences in the tissue including persistent infiltration by inflammatory cells that activates a type of cell known as fibro-adipogenic precursor cells (FAPs). FAPs contribute to muscle degeneration as they produce fat and fibrotic tissue which substitutes the damaged muscle fibers. During disease's progression, loss of fibers is associated to expansion of fibrotic and fatty tissue which impairs the capability of satellite cells to regenerate damaged muscle fibers. Although several molecules have been identified as key to regulate this process in mice, little is known in humans what is limiting the development of new treatments. We have developed a new protocol to isolate satellite cells and FAPs from muscle biopsies that were taken for diagnosis and are stored in biobanks. We have analyzed the cells obtained from DMD and healthy people and have identified different types of FAP cells. To summarize we have identified two main populations, one that is actively proliferating and retain stemness properties and another that is already committed to produce fibrotic tissue. In this proposal we will explore when these different populations appear in the progression of DMD patients using muscle biopsies of patients at different clinical stages and correlate their presence with tissue features to understand if these subpopulations are associated to changes such as fibrosis, inflammation or muscle fiber death. Then we will analyze the genes that are expressed in control and DMD muscle by fibers but also by other components, such as inflammatory cells, that could guide the changes in FAP subtype. Understanding the molecular pathways governing the changes in FAP subpopulations will provide potential new targets for therapies aimed to counteract the expansion of fibro-fatty tissue. In a third stage we will isolate the subpopulations of FAPs and study their properties including how they proliferate, move, or differentiate into fibrotic or fat producing cells and how they interact with satellite cells. These later studies provide information about how two cells interact in a dish, as it would happen when they are in the tissue. We will study this interaction both in standard 2D culture dishes, but also in 3D systems using printed molds that enable a more perdurable and structured generation of artificial muscles. These experiments will provide valuable information to understand if and how FAPs influence satellite cell function. Finally, we will test libraries of drugs able to counteract the function of key molecular pathways identified in the previous experiments to understand if they are able to modulate the function of FAPs.
杜氏肌营养不良症(DMD)是一种破坏性的疾病所产生的突变的肌营养不良基因。疾病的发病伴随虚弱的发作发生在5岁之前,并且在青春期期间进展导致肌肉松弛。患者在生命的第三个十年期间死于心脏或呼吸系统并发症。迄今为止唯一批准的治疗方法是皮质激素,它可以减缓疾病进展,但对自然史没有真实的影响。尽管投入了巨大的努力来开发新的治疗方法,但大多数都失败了。目前,基于向肌肉纤维释放健康的抗肌萎缩蛋白基因拷贝的基因疗法显示出有希望的结果,但似乎很明显,它们无法阻止疾病的进展,肌肉退化的过程将保持活跃。DMD的肌肉变性过程已经在该疾病的动物模型中研究了多年。肌营养不良蛋白的缺乏使纤维在正常肌肉收缩时更容易受到损伤。受损的纤维最初由称为卫星细胞的细胞修复。然而,重复性损伤在组织中引发了一系列后果,包括炎症细胞的持续浸润,这些炎症细胞激活了一种称为纤维脂肪形成前体细胞(FAP)的细胞。FAP导致肌肉退化,因为它们产生脂肪和纤维化组织,替代受损的肌肉纤维。在疾病的进展过程中,纤维的损失与纤维化和脂肪组织的扩张有关,这损害了卫星细胞再生受损肌纤维的能力。尽管已经确定了几种分子是调节小鼠这一过程的关键,但人类对限制新治疗方法发展的因素知之甚少。我们已经开发了一种新的协议,从肌肉活检中分离卫星细胞和FAP,这些肌肉活检用于诊断并储存在生物库中。我们分析了从DMD和健康人中获得的细胞,并鉴定了不同类型的FAP细胞。总而言之,我们已经确定了两个主要群体,一个是积极增殖和保留干性性质,另一个是已经致力于产生纤维化组织。在本提案中,我们将使用不同临床阶段患者的肌肉活检来探索这些不同人群何时出现在DMD患者的进展中,并将其存在与组织特征相关联,以了解这些亚群是否与纤维化,炎症或肌纤维死亡等变化相关。然后,我们将分析在对照和DMD肌肉中表达的基因,这些基因由纤维以及其他成分(如炎症细胞)表达,这些成分可以指导FAP亚型的变化。了解控制FAP亚群变化的分子途径将为旨在对抗纤维脂肪组织扩张的治疗提供潜在的新靶点。在第三阶段,我们将分离FAP的亚群并研究它们的特性,包括它们如何增殖,移动或分化成纤维化或脂肪产生细胞以及它们如何与卫星细胞相互作用。这些后来的研究提供了关于两个细胞如何在培养皿中相互作用的信息,因为它们在组织中时会发生这种情况。我们将在标准的2D培养皿中研究这种相互作用,也将在使用打印模具的3D系统中研究这种相互作用,这些模具能够更持久和结构化地生成人造肌肉。这些实验将提供有价值的信息,以了解FAP是否以及如何影响卫星细胞功能。最后,我们将测试能够抵消先前实验中确定的关键分子通路功能的药物库,以了解它们是否能够调节FAP的功能。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Analysis of muscle magnetic resonance imaging of a large cohort of patient with VCP-mediated disease reveals characteristic features useful for diagnosis.
  • DOI:
    10.1007/s00415-023-11862-4
  • 发表时间:
    2023-12
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Esteller, Diana;Schiava, Marianela;Villar-Quiles, Rocio-Nur;Dibowski, Boris;Venturelli, Nadia;Laforet, Pascal;Alonso-Perez, Jorge;Olive, Montse;Dominguez-Gonzalez, Cristina;Paradas, Carmen;Velez, Beatriz;Kostera-Pruszczyk, Anna;Kierdaszuk, Biruta;Rodolico, Carmelo;Claeys, Kristl;Pal, Endre;Malfatti, Edoardo;Souvannanorath, Sarah;Alonso-Jimenez, Alicia;de Ridder, Willem;De Smet, Eline;Papadimas, George;Papadopoulos, Constantinos;Xirou, Sofia;Luo, Sushan;Muelas, Nuria;Vilchez, Juan J.;Ramos-Fransi, Alba;Monforte, Mauro;Tasca, Giorgio;Udd, Bjarne;Palmio, Johanna;Sri, Srtuhi;Krause, Sabine;Schoeser, Benedikt;Fernandez-Torron, Roberto;Lopez de Munain, Adolfo;Pegoraro, Elena;Farrugia, Maria Elena;Vorgerd, Mathias;Manousakis, Georgious;Chanson, Jean Baptiste;Nadaj-Pakleza, Aleksandra;Cetin, Hakan;Badrising, Umesh;Warman-Chardon, Jodi;Bevilacqua, Jorge;Earle, Nicholas;Campero, Mario;Diaz, Jorge;Ikenaga, Chiseko;Lloyd, Thomas E.;Nishino, Ichizo;Nishimori, Yukako;Saito, Yoshihiko;Oya, Yasushi;Takahashi, Yoshiaki;Nishikawa, Atsuko;Sasaki, Ryo;Marini-Bettolo, Chiara;Guglieri, Michela;Straub, Volker;Stojkovic, Tanya;Carlier, Robert Y.;Diaz-Manera, Jordi
  • 通讯作者:
    Diaz-Manera, Jordi
Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice.
  • DOI:
    10.3390/biomedicines10102629
  • 发表时间:
    2022-10-19
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Alonso-Perez, Jorge;Carrasco-Rozas, Ana;Borrell-Pages, Maria;Fernandez-Simon, Esther;Pinol-Jurado, Patricia;Badimon, Lina;Wollin, Lutz;Lleixa, Cinta;Gallardo, Eduard;Olive, Montse;Diaz-Manera, Jordi;Suarez-Calvet, Xavier
  • 通讯作者:
    Suarez-Calvet, Xavier
Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis
  • DOI:
    10.1016/j.nmd.2023.08.010
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Esteller,Diana;Morrow,Jasper;Diaz-Manera,Jordi
  • 通讯作者:
    Diaz-Manera,Jordi
RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy.
  • DOI:
    10.1002/jcsm.12923
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fernández-Simón E;Suárez-Calvet X;Carrasco-Rozas A;Piñol-Jurado P;López-Fernández S;Pons G;Bech Serra JJ;de la Torre C;de Luna N;Gallardo E;Díaz-Manera J
  • 通讯作者:
    Díaz-Manera J
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jordi Diaz-Manera其他文献

Reaching consensus on comprehensive and achievable monitoring for adults with late-onset Pompe disease in the UK
就英国晚期庞贝病成人的全面且可实现的监测达成共识
  • DOI:
    10.1016/j.ymgme.2024.108698
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Patrick Deegan;Jordi Diaz-Manera;Tarekegn Geberhiwot;Derralynn Hughes;Meredith K. James;David Moreno Martinez;Elizabeth Morris;Azza Osman;Michael I. Polkey;Mark Roberts;Robin Lachmann
  • 通讯作者:
    Robin Lachmann
strongNEO1/NEO-EXT studies: Long-term muscle quantitative magnetic resonance imaging and functional efficacy in adults with late-onset Pompe disease (LOPD) on avalglucosidase alfa treatment/strong
StrongNeo1/neo-Ext研究:长期肌肉定量磁共振成像和功能疗效在患有晚期发作的庞贝疾病(LOPD)上的avalglucosidase ass Alfa治疗/强
  • DOI:
    10.1016/j.ymgme.2023.107783
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Barry Byrne;Pierre G. Carlier;John Vissing;Mazen M. Dimachkie;Richard Barohn;Priya S. Kishnani;Shafeeq Ladha;Eugen Mengel;Sabrina Sacconi;Jaya Trivedi;Peter Young;Kristina An Haack;Nicole Armstrong;Patrick Miossec;Nathan Thibault;Susan Sparks;Benedikt Schoser;Jordi Diaz-Manera
  • 通讯作者:
    Jordi Diaz-Manera
strongAvalglucosidase alfa improves motor and respiratory function in late-onset Pompe disease: A COMET win-ratio analysis/strong
强力α-艾杜糖醛酸苷酶改善晚发型庞贝病的运动和呼吸功能:一项彗星胜率分析
  • DOI:
    10.1016/j.ymgme.2022.107076
  • 发表时间:
    2023-02-01
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Jordi Diaz-Manera;Mazen M. Dimachkie;Jack Ishak;Jaime Caro;Alaa Hamed;Lionel Riou França;Nathan Thibault;Pragya Shukla;Kenneth I. Berger;Matthias Boentert
  • 通讯作者:
    Matthias Boentert
strongNonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of avalglucosidase alfa vs alglucosidase alfa/strong
对 COMET 试验中用力肺活量的强非参数分析显示阿糖苷酶α优于阿糖苷酶α/强
  • DOI:
    10.1016/j.ymgme.2022.107077
  • 发表时间:
    2023-02-01
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Jordi Diaz-Manera;Mazen M. Dimachkie;Emmanuelle Salort-Campana;Shahram Attarian;Kenneth I. Berger;Magali Periquet;Patrick Miossec;Nathan Thibault;Tianyue Zhou;Matthias Boentert
  • 通讯作者:
    Matthias Boentert
strongEffect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL/strong
在ERT经验经验的成年人中,cipaglucosidase alfa和miglustat的cipagaucosidase alfa和miglustat的质量分析与藻糖苷酶阿尔法的抗葡萄糖苷酶Alfa在促进/强的成年人中患有晚期发作的庞贝
  • DOI:
    10.1016/j.ymgme.2023.107971
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Tahseen Mozaffar;Drago Bratkovic;Barry J. Byrne;Kristl G. Claeys;Jordi Diaz-Manera;Mazen M. Dimachkie;Priya S. Kishnani;Hani Kushlaf;Mark E. Roberts;Antonio Toscano;Jeffrey Castelli;Fred K. Holdbrook;Sheela Sitaraman Das;Yasmine Wasfi;Benedikt Schoser
  • 通讯作者:
    Benedikt Schoser

Jordi Diaz-Manera的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

基于DMD的小型化、高灵敏度SPR光谱检测技术研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    15.0 万元
  • 项目类别:
    省市级项目
光透明成像研究DMD小鼠骨骼肌神经肌肉接头三维整体精细结构特征及变化
  • 批准号:
    82372012
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
DMD1调控甜瓜属作物线粒体父系遗传的分子机制研究
  • 批准号:
    32372692
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
Wnt7a激活Celsr2蛋白提高肌卫星细胞基因编辑效率改善基因编辑治疗DMD疗效的研究
  • 批准号:
    82301588
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
ADAR蛋白介导外显子跳跃治疗人源化DMD小鼠的研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
DMD基因非典型变异的异常剪接机制及其治疗作用研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于大片段定点敲入技术实现自体干细胞移植治疗DMD的实验研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
组合DMD时空调制数字光刻及其在光纤器件微加工中的应用
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
MRCK和SNCA介导的磷酸化促进肌肉萎缩蛋白DMD泛素化降解的作用机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
Lnc-mg参与miR-125b靶向调控Akt/GSK-3β以减轻糖皮质激素对DMD模型鼠成肌分化抑制的研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目

相似海外基金

DMDを用いた膜状・糸状揚水の生成メカニズム解明と液滴・液糸生成装置の開発
利用 DMD 阐明膜/丝抽水的生成机制以及液滴/液体生成装置的开发
  • 批准号:
    24K07316
  • 财政年份:
    2024
  • 资助金额:
    $ 107.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SDHAF4発現低下はDMD患者iPS細胞由来心筋細胞でミトコンドリア機能異常を引き起こす
SDHAF4 表达减少导致 DMD 患者 iPS 细胞来源的心肌细胞线粒体功能异常
  • 批准号:
    24K18857
  • 财政年份:
    2024
  • 资助金额:
    $ 107.87万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
マルチオミクス解析を用いた、DMD筋への細胞治療時における運動による作用機序の解明
利用多组学分析阐明运动在 DMD 肌肉细胞治疗过程中的作用机制
  • 批准号:
    24K14347
  • 财政年份:
    2024
  • 资助金额:
    $ 107.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors
工程组织阵列可简化去免疫 DMD 基因治疗载体
  • 批准号:
    10724882
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
    Fellowship
Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD)
开发 Utropin 位点封闭寡核苷酸 (SBO) 来治疗杜氏肌营养不良症 (DMD)
  • 批准号:
    10678195
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD
MyoPAXon 的系统移植:治疗 DMD 的 IND 启用研究
  • 批准号:
    10822639
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
3D Bioprinted Human Model of Duchenne Muscular Dystrophy (DMD) Cardiomyopathy to Study Disease Progression with Imposed Force and Precise Gene Editing
杜氏肌营养不良症 (DMD) 心肌病的 3D 生物打印人体模型,通过施加力和精确的基因编辑来研究疾病进展
  • 批准号:
    10628962
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
Controllable base editing therapy for DMD
DMD 的可控碱基编辑疗法
  • 批准号:
    10728698
  • 财政年份:
    2023
  • 资助金额:
    $ 107.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了